Immunotherapy Combined with Radiation Fails to Improve Glioblastoma Outcomes in Recent Trial

A recent phase II/III clinical trial conducted by NRG Oncology has demonstrated that combining immune checkpoint inhibitors, ipilimumab and nivolumab, with radiation therapy does not enhance progression-free survival (PFS) for patients with newly diagnosed glioblastoma characterized by unmethylated MGMT promoter status. The trial, known as NRG-BN007, involved 159 eligible participants who were randomized to receive either the immunotherapy combination or standard treatment with temozolomide (TMZ), alongside radiation therapy. Results showed no significant difference in PFS between the two groups, with median PFS of 7.7 months for the immunotherapy group versus 8.5 months for the TMZ group. The hazard ratio was 1.47, indicating no advantage of the experimental treatment.

Further analysis revealed that overall survival data remains immature, but preliminary data suggests similar survival durations in both arms, around 13 months. Due to the lack of benefit observed in PFS, the trial will not advance to a phase III study focusing on overall survival. These findings are particularly noteworthy given that glioblastoma is the most common primary brain cancer in adults and traditionally has a poor prognosis despite current treatments, which include surgery, radiotherapy, and chemotherapy with TMZ.

Importantly, the majority of newly diagnosed glioblastoma cases exhibit an unmethylated MGMT promoter, making them more resistant to TMZ. Hence, finding effective therapies for this subgroup remains a critical challenge. The trial's outcome underscores the need for continued research to identify more promising approaches, especially for this difficult-to-treat population.

Lead researcher Dr. Andrew B. Lassman emphasized that although the combination therapy did not yield improved PFS, the trial provides valuable insights that will steer future research. Biomarker analyses are ongoing to ascertain whether specific patient subsets might benefit from immunotherapy, and further follow-up is required to assess overall survival outcomes.

This study highlights the ongoing efforts to improve glioblastoma treatment and the importance of rigorous clinical trials to validate potential therapies. The findings are published in the Journal of Clinical Oncology and contribute significantly to the understanding of glioblastoma management.

Source: https://medicalxpress.com/news/2025-08-trial-immunotherapy-glioblastoma-outcomes.html